Rapporter | 31 Mar 2023 | Biosergen

Biosergen AB: Biosergen publishes interim report for fourth quarter 2022

Summary of the Interim Report for Q4 2022

2022 2021 2022 2021
TSEK Oct-Dec Oct-Dec Jan-Dec Jan-Dec

Other income 1.964 3.290 5.183 8.573
Profit/loss before depreciation (EBITDA) -12.491 -9.876 -39.987 -34.077
Operating profit/loss befor net financials -12.491 -9.876 -39.987 -34.077
Net financials 87 -83 109 -240
Netprofit/loss for the period -12.432 -9.959 -39.906 -34.318

Earnings per share (SEK) -0,40 -0,35 -1,28 -1,22

Highlights during Q4 2022

• October 4, Biosergen announces the outcome in the rights issue
• December 12, The first volunteer has been dosed in the MAD part of the Phase I trial of BSG005.

Highlights after the period

• January 16, Biosergen completes the first Multiple Ascending Dose (MAD) cohort of BSG005 phase I trial.
• March 13, Positive topline data from phase 1 study of BSG005 shows it is safe and well tolerated. It gives hope for a change in the treatment paradigm of patients with invasive fungal infections.
• March 29, Biosergen provides Phase 2 clinical development strategy update.

The Financial report can be found on our website: https://biosergen.net/investors/filings

Annual Report

The annual report was planned to be published on April 6. It will now be disclosed on May 10 due to the work with the annual report has taken longer time then previously expected.

Biosergen will conveine its Annual General Meeting May 31.